| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 39.8 | 61.0 | 34.2 |
| Other income | 2.0 | 1.3 | 2.3 |
| Total income | 41.8 | 62.3 | 36.5 |
| Profit before exceptional items & tax | 4.9 | 5.0 | 5.9 |
| Profit before tax | 4.9 | 4.7 | 5.9 |
| Net profit | 4.7 | 4.5 | 5.0 |
| Operating margin | 11.7% | 7.5% | 16.2% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -6.00% |
|---|---|
| Net profit, quarter on quarter | +4.40% |
| Revenue, year on year | +16.40% |
| Operating profit, year on year | -19.40% |
| Operating profit, quarter on quarter | -21.60% |
BSE results filing, NSE: GENNEX. Figures extracted from the filing.
Gennex Laboratories Ltd: key numbers
- Share price
- ₹9.99
- Market cap
- ₹242.7 Cr
- Revenue (annual)
- ₹172.7 Cr
- Net profit (annual)
- ₹20.98 Cr
- P/E (TTM)
- 10.3×Sector 47.4×
- Promoter holding
- 23.63%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gennex Laboratories Ltd
All →Gennex Laboratories Business Update
Subsidiary Deccan Remedies Ltd received approvals from the Drug Control Administration, Andhra Pradesh, to manufacture ten additional pharmaceutical products and test licences at its facility.
Gennex Laboratories Annual General Meeting
Gennex Laboratories Limited announced the closure of its register of members from September 23 to September 30, 2026. This is for the upcoming 41st Annual General Meeting.
Gennex Laboratories Board Meeting Outcome
Gennex Laboratories announced the outcome of its board meeting, approving the draft directors' report and scheduling the 41st Annual General Meeting for September 30, 2026.
Gennex Laboratories Board Meeting Date
Gennex Laboratories has announced a board meeting scheduled for September 4, 2026, to discuss the upcoming 41st Annual General Meeting and other business matters.
Gennex Laboratories Board Meeting Date
Gennex Laboratories scheduled a board meeting for August 14, 2026. The board will review unaudited financial statements for the June 30, 2026 quarter.
Gennex Laboratories Other Announcement
Gennex Laboratories Ltd filed its quarterly shareholding pattern. The company has applied for trading approval for 1.55 crore shares issued via warrant conversion.